A Comparative Pharmacokinetics and Safety Study of OvaRex MAb-B43.13 in Patients With Ovarian Epithelial Carcinoma

Inclusion Criteria: * Histological diagnosis of epithelial adenocarcinoma of ovarian, tubal or peritoneal origin. * FIGO Stage III or IV prior to study. * Serum CA125 level \>35 U/mL prior to or at initial surgery. Alternatively, serum CA125 level \> or = 100 U/mL following surgery or immunohistochemical evidence of tumor tissue expressing CA125. * Completed primary treatment following initial diagnosis, including chemotherapy involving a cisplatin or carboplatin-based regimen. * Functional Performance Status \< or = 2 by ECOG scale. * Medical assessment consistent with prognosis for an expected survival of at least 3 months. * Voluntary participation, signed informed consent and willingness to complete all study procedures. Exclusion Criteria: * No surgery (not including minor surgical procedures), chemotherapy, or radiotherapy (whole abdomen, abdominopelvic or pelvic) within 4 weeks prior to first dose of study drug. * No known refractory or recurrent disease requiring chemotherapy during the 4 weeks prior to, or planned 10 weeks after first study dose. * Serum CA125 levels not \>800 U/mL at baseline evaluation. * No gross (clinically evident) ascites. * No immunotherapy (interferons, tumor necrosis factor, other cytokines or biological response modifiers, or BCG vaccines) within the previous 4 weeks of first study dose. * No previous treatment with murine monoclonal antibodies for diagnostic or therapeutic purposes or serum human anti-murine antibodies (HAMA) not above upper limit of normal at baseline evaluation. * Not on long-term chronic treatment with immunosuppressive drugs such as cyclosporin, ACTH, or corticosteroids. * Ovarian tumors must be of low malignant potential or with noninvasive disease. * No concurrent malignancy (except non-melanoma of the skin or in situ carcinoma of cervix), unless curative treatment was received and patient has been disease-free for \> or = 5 years. * No known allergy to murine proteins, or prior documented anaphylactic reaction to any drug, or known hypersensitivity to diphenhydramine or other antihistamines of similar chemical structure. * No previous splenectomy. * No active autoimmune disease (e.g., rheumatoid arthritis, SLE, ulcerative colitis, Chrohn's Disease, MS, ankylosing spondylitis). * No recognized immunodeficiency disease including cellular immunodeficiencies, hypogammaglobulinemia or dysgammaglobulinemia; no acquired, hereditary, or congenital immunodeficiencies. * No uncontrolled diseases or illness other than this cancer. * No significant cardiovascular abnormalities including uncontrolled hypertension, uncontrolled angina, uncontrolled arrhythmias, or CHF (NYHA Classes II-IV). * No compromised hematopoietic function defined as a hemoglobin \<10.0 g/dL or lymphocyte count \<300 mm3 or neutrophil count \<1000 mm3 or platelet count \<100,000 mm3. * No hepatic dysfunction defined as a bilirubin above upper limit of normal, LDH, SGOT and SGPT \>2 times upper limits of normal, or albumin \<3.5 g/dL. * No renal dysfunction defined as serum creatinine above upper limit of normal. * No pregnancy or breast-feeding (While pregnancy is unlikely in view of the disease and previous surgery, patients who the investigator considers may be at risk of pregnancy will have a pregnancy \[beta-HCG\] test and will be using a medically approved contraceptive method.) * No other investigational drugs within 30 days of enrollment. * No contraindications present to the use of pressor agents. * No HIV infection, or recent history of drug abuse, alcoholism, or hepatitis.